The third quarter will see important data for Travere, Radius and Sio Gene, among other small developers.
Novartis makes progress with its most valuable pipeline asset, but others also hope to make a mark in IgA nephropathy.
Our final look at upcoming catalysts sees data expected from Replimune, TCR2 Therapeutics, Anavex and more.
Genkyotex had nearly run out of money after a crippling clinical failure, but today pulled a rabbit out of the hat.
Loosening of clinical requirements has encouraged more projects into the IgA nephropathy pipeline, with a steroid–based approach from Sweden’s Calliditas looking…
Biotech IPOs raised a huge $2.3bn on Western exchanges in the second-quarter of 2018, as private companies rushed to market ahead of the summer lull.